Avalo Therapeutics Inc
C6K0
Company Profile
Business description
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
Contact
1500 Liberty Ridge Drive
Suite 321
WaynePA19087
USAT: +1 410 522-8707
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
33
Stocks News & Analysis
stocks
Expanding store network for ASX listed retailer
Sales growth but lack of margin expansion due to competition.
stocks
SpaceX jumps 19% in debut, but hurdles lie ahead
Pre-IPO holders could start selling later this summer, and earnings will be an important test.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,128.30 | 14.90 | 0.16% |
| CAC 40 | 8,350.87 | 150.08 | 1.83% |
| DAX 40 | 24,635.30 | 425.59 | 1.76% |
| Dow JONES (US) | 51,202.26 | 353.51 | 0.70% |
| FTSE 100 | 10,471.72 | 167.84 | 1.63% |
| HKSE | 24,839.70 | 121.60 | 0.49% |
| NASDAQ | 25,888.84 | 79.18 | 0.31% |
| Nikkei 225 | 69,320.37 | 3,300.33 | 5.00% |
| NZX 50 Index | 13,360.59 | 33.28 | -0.25% |
| S&P 500 | 7,431.46 | 37.16 | 0.50% |
| S&P/ASX 200 | 8,913.80 | 6.80 | 0.08% |
| SSE Composite Index | 4,080.22 | 48.70 | 1.21% |